Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors
Status: Archived
TGen Clinical Research Service
mi
from
Scottsdale, AZ
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
TGen Clinical Research Service
mi
from
Scottsdale, AZ
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors
Status: Archived
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC)
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC)
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Status: Archived
Oregon Health and Science University
mi
from
Portland, OR
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
mi
from
Portland, OR
STAT3 Inhibitor for Solid Tumors
A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
STAT3 Inhibitor for Solid Tumors
A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
STAT3 Inhibitor for Solid Tumors
A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
STAT3 Inhibitor for Solid Tumors
A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Washington University
mi
from
St. Louis, MO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Ohio State University
mi
from
Columbus, OH
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
San Bernandino Urology
mi
from
San Bernardino, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
San Bernandino Urology
mi
from
San Bernardino, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Comprehensive Cancer Care Centers of Nevada
mi
from
Henderson, NV
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Comprehensive Cancer Care Centers of Nevada
mi
from
Henderson, NV
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Greenville Hospital System Univeristy Medical Center
mi
from
Greenville, SC
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Greenville Hospital System Univeristy Medical Center
mi
from
Greenville, SC
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
University of Washington; UW Medical Center
mi
from
Seattle, WA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
mi
from
Seattle, WA
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Providence Medical Group
mi
from
Terre Haute, IN
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Providence Medical Group
mi
from
Terre Haute, IN
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Norton Cancer Institute
mi
from
Louisville, KY
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Norton Cancer Institute
mi
from
Louisville, KY
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
CCOP - Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
CCOP - Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Status: Archived
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Caphosol in Sarcoma Patients With Mucositis
A Phase II Study to Evaluate the Preliminary Efficacy Assessment of Caphosol in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide or Cisplatin
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Caphosol in Sarcoma Patients With Mucositis
A Phase II Study to Evaluate the Preliminary Efficacy Assessment of Caphosol in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide or Cisplatin
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.
Status: Archived
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors
Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors
Status: Archived
Children's Doctor
mi
from
Houston, TX
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors
Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Doctor
mi
from
Houston, TX
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors
Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors
Status: Archived
Emory University
mi
from
Atlanta, GA
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors
Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Children's Doctor
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Children's Doctor
mi
from
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Emory University
mi
from
Atlanta, GA
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Emory University
mi
from
Atlanta, GA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
St. Jude Heritage Healthcare
mi
from
Fullerton, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
St. Jude Heritage Healthcare
mi
from
Fullerton, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Georgia Cancer Specialists
mi
from
Atlanta, GA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
Georgia Cancer Specialists
mi
from
Atlanta, GA